Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Akums Drugs & Pharmaceuticals Ltd. (AKUMS.NS)
Delhi, IN
Akums Drugs & Pharmaceuticals Ltd. is an Indian-based company, established in 2004 and headquartered in Delhi, that operates globally as a manufacturer and supplier of both finished pharmaceutical products and active pharmaceutical ingredients (APIs). Its diverse product range encompasses conventional drugs, traditional Ayurvedic and herbal remedies, personal care items including toiletries, nutraceuticals, food and dietary supplements, dermatological and cosmetic products, and healthcare and hospital supplies, along with over-the-counter (OTC) solutions. The company also deals in excipients and various chemical compounds. Akums develops and markets its own branded formulations across a variety of dosage forms, such as tablets, capsules, injectables, ophthalmic preparations, and soft gelatin capsules. These products address a broad spectrum of therapeutic areas, including gynaecology, cardiology, orthopaedics, pediatrics, dermatology, anti-infectives, pain management, and gastroenterology. Furthermore, Akums Drugs & Pharmaceuticals provides services as a pharmaceutical contract development and manufacturing organization (CDMO).
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.54% | -1.56% | -4.64% | +6.29% | +20.73% | +14.56% | -5.90% | -34.73% | -34.73% | -34.73% | -34.73% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+7.1% ★ Q1'26: +14.8% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-26.2% Q1'26: -43.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+20.0% ★ Q1'26: +89.8% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+8.4% Q1'26: +9.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+13.6% ★ Q1'26: +16.6% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+2.3% Q1'26: +1.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.30× ★ Q1'26: 0.26× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2025 actual |
Mar 2026 3 Rev. Ana. 2 EPS Ana. |
Mar 2027 3 Rev. Ana. 2 EPS Ana. |
Mar 2028 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|
| Revenue |
40.71B
est: 40.80B (-0.2%)
|
43.60B
42.34B – 44.33B
+6.9% YoY
|
49.26B
48.26B – 49.77B
+13.0% YoY
|
56.93B
55.42B – 58.01B
+15.6% YoY
|
| EBITDA |
5.29B
est: 10.59B (-50.0%)
|
11.31B
10.99B – 11.50B
+6.9% YoY
|
12.78B
12.52B – 12.92B
+13.0% YoY
|
14.77B
14.38B – 15.05B
+15.6% YoY
|
| EBIT |
3.76B
est: 8.80B (-57.3%)
|
9.40B
9.13B – 9.56B
+6.9% YoY
|
10.62B
10.41B – 10.73B
+13.0% YoY
|
12.27B
11.95B – 12.51B
+15.6% YoY
|
| Net Income |
3.38B
est: 2.66B (+27.3%)
|
2.55B
2.50B – 2.80B
-3.9% YoY
|
3.76B
3.55B – 3.87B
+47.5% YoY
|
5.06B
4.69B – 5.27B
+34.5% YoY
|
| SGA |
1.03B
est: 1.93B (-47.0%)
|
2.07B
2.01B – 2.10B
+6.9% YoY
|
2.34B
2.29B – 2.36B
+13.0% YoY
|
2.70B
2.63B – 2.75B
+15.6% YoY
|
| EPS |
22.60
est: 17.35 (+30.2%)
|
17.10
16.30 – 18.31
-1.4% YoY
|
24.30
23.22 – 25.28
+42.1% YoY
|
32.40
30.65 – 34.45
+33.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-15 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets ex-China Equity ETF AVXC | 0.01% | 23.9K | 0.33% |
| 2 | Avantis Emerging Markets Equity UCITS ETF USD Acc AVEM.L | 0.00% | 8.8K | 0.35% |
| 3 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 222.8K | 0.33% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sanjeev Jain | Co-Founder, MD & Whole Time Director | 83M | male |
| Sandeep Jain | Co Founder, MD & Director | 82M | male |
| Sanjay Kumar Sinha | President of Operations & Whole Time Director | 13M | male |
| Sahil Maheshwari | General Manager of Strategy | — | — |
| Sanjay Sharma | President of Strategy, New Projects & Business Excellence | — | male |
| Shantanu R. Chobhe | President of CQA Formulation | — | male |
| Arushi Jain | Director of Corporate Growth & Excellence | — | female |
| Sumeet Sood | Chief Financial Officer | — | male |
| Arvind Srivastava | President of Human Resource | — | male |
| Dharamvir Malik | Company Secretary & Compliance Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AKUMS.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
